Menarini Silicon Biosystems Inc.

Menarini Silicon Biosystems is a clinical laboratory and diagnostic services company specializing in non-invasive biomarker detection and cell-based assays for oncology and precision medicine applications. The company is part of the Menarini Group and operates as a CLIA-certified laboratory offering proprietary circulating tumor cell (CTC) detection platforms and phenotyping services. Primary product is CELLSEARCH®, the first and only FDA-cleared actionable test for detecting and enumerating circulating tumor cells in patients with metastatic breast, prostate, and colorectal cancer, with clinical utility demonstrated in guiding therapeutic strategy and monitoring disease progression. The company also offers CELLSEARCH® Circulating Multiple Myeloma Cell Test for minimally invasive serological monitoring via blood draw, and emerging cell-based non-invasive prenatal testing (NIPT) technology for detection of fetal genomic abnormalities. Services include biomarker phenotyping, clinical laboratory testing for biopharma clinical trials, and comprehensive research support. The company serves oncology centers, biopharma sponsors, and healthcare systems requiring standardized, reliable CTC enumeration and biomarker profiling for patient stratification, treatment monitoring, and drug development. Quality and regulatory compliance are core operational principles.